Although undesirable efficacy and severe off-target toxicity were still major challenges of CAR-T therapy in R/R AML, new targets were still being investigated, such as CD123 (NCT04265963), Siglec-6 (NCT05488132), IL1RAP (NCT04169022) and FLT3 (NCT05023707). The gene discussed is FLT3; the disease is acute myeloid leukemia.